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A b s t r a c t
Background: The biochemical confirmation of myocardial infarction is based on cardiac troponin (cTnI or cTnT) determination. 
Recent scientific results suggested that microRNAs (miRNAs) might become a new biomarker of tissue injury. 
Aim: To evaluate the release kinetics of circulating heart-specific miRNA-208a and also to test the hypothesis that miRNA-208a 
can serve as an accessible, diagnostically sensitive plasma biomarker of ST-elevation acute myocardial infarction (STEMI).
Methods: Nineteen STEMI patients (four women and 15 men, aged 44–85 years), 12 patients with stable coronary artery 
disease (CAD), and eight patients with a negative observation of CAD as a control group were studied. Blood samples were 
collected on admission and at three, six, 12, 24, and 48 h afterwards; in the CAD and control group blood samples were taken 
only once. Plasma levels of miRNA-208a determined by real-time polymerase chain reaction and their relative fold changes 
were calculated. cTnI and creatinine kinase (CK)-MB mass were also measured in the patients’ serum samples. 
Results: miRNA-208a was increased in STEMI patients at the time of admission and nearly undetectable in CAD patients and 
controls. The peak of miRNA-208a was observed at 3 h after reperfusion (p < 0.001). The traditional biomarkers (cTnI and 
CK-MBmass), which increase later in comparison to miRNA-208a reaching the maximum concentrations 6 h after reperfusion, 
were observed. Circulating miRNA-208a levels strongly correlated with cTnI and CK-MBmass released from the infarcted area. 
Conclusions: These results demonstrate that plasma miRNA-208a is an interesting and promising candidate for a new bio-
marker released early after onset of myocardial infarction.
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INTRODUCTION
Early identification of myocardial infarction (MI) in chest pain 
patients is crucial for early treatment initiation. Diagnosis of acute 
myocardial infarction (AMI) relies, besides clinical symptoms 
and electrocardiographic (ECG) findings, primarily on biomarker 
level [1]. High-sensitivity cardiac troponin (hs-cTnI) assays add 
a new dimension to the assessment of chest pain patients [2, 3]. 
These assays detect lower concentrations of cardiac troponin 
(cTnI), which made it possible to shorten the time to AMI. 
However, since they also detect a variety of acute and chronic 
coronary conditions that are not associated with an AMI, the 
positive predictive value of an elevated cTnI for an AMI has 
decreased, causing confusion about how best to use hs-cTnI in 
the clinical setting [4]. Therefore, the ideal biomarker for rapid 
and reliable diagnosis of AMI is still lacking. Scientific approaches 
should involve the analysis of multiple biomarkers that cover 
different aspects of the pathophysiological processes associated 
with disease progression. The dynamic development of analyti-
cal techniques in molecular biology has defined new directions 
for research on an ideal biomarker in myocardial necrosis.
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MicroRNAs (miRNAs) are short, single-stranded, non-cod-
ing RNA molecules consisting of 16–29 nucleotides, whose 
primary function is the negative regulation of gene expression 
(so-called “sleep genes”). The mechanism of action involves 
binding of miRNAs to specific non-translated 3’ regions of 
the mRNA, which results in the destabilisation and block-
ing translation of the transcripts [5, 6]. It is estimated that 
about 60% of the transcriptome of mammals is regulated by 
miRNA [7]. Therefore, since its discovery, miRNA is an object 
of interest as a molecule controlling many physiological pro-
cesses, such as differentiation and proliferation of stem cells, 
neurogenesis, angiogenesis, and pathological conditions such 
as carcinogenesis or endothelial dysfunction and myocardial 
hypertrophy. In particular, molecules miRNA-1, -133, -195, 
and -208a affect proliferating cardiomyocytes and myocardial 
hypertrophy [8]. It seems that the small molecule miRNA-208a 
released from cardiomyocytes to plasma may be an almost 
perfect biochemical marker of ischaemia prior to cell necrosis. 
Therefore, the immediate goal of the our study was 
a quantitative assessment of circulating miRNA-208a in pa-
tients with ST elevation MI (STEMI) both at initial presentation 
and during the course of AMI up to 48 h. We also compared 
the changes of the miRNA-208a expression in plasma with 
cTnI and creatinine kinase (CK)-MB mass concentration 
in serum.
METHODS
This was a prospective, observational, open-label study. Par-
ticipation in the study had no effect on therapeutic decisions, 
invasive procedures, and the course of hospitalisation. The 
study received approval from the bioethical committee of the 
Medical University of Warsaw. Patients were enrolled during 
the years 2010–2012.
Study population
All 39 patients signed an informed consent form to participate 
in the research. Based on the initial diagnosis they were al-
located to one of three groups:
 — STEMI group (n = 19) included patients with acute 
STEMI, who were admitted to the hospital within the 
first 3 h after the onset of symptoms. The initial diagnosis 
was based on the presence of chest pain or its equivalent 
and persistent ECG ST-segment elevations (at least 2 mm 
in two adjacent leads), all patients underwent coronary 
angiography according to medical indications;
 — stable CAD group (n = 12) included patients with sta-
ble symptomatic coronary artery disease (CAD) who 
underwent elective coronary angiography according to 
medical indications;
 — control group (n = 8) included patients who had a nega-
tive observation of CAD. 
The blood sample in each case was taken before coronary 
revascularisation. All patients had a coronary angio graphy, 
and then according to the indications, percutaneous coronary 
intervention (PCI) of infarct-related coronary artery was per-
formed.
The exclusion criteria were: lack of written consent, not 
meeting the criteria for inclusion, paraneoplastic syndromes, 
severe anaemia (with a concentration of a blood haemoglobin 
less than 7 g/dL), history of chronic heart failure in New York 
Heart Association class III or IV, or the presence of acute severe 
heart failure (pulmonary oedema and/or cardiogenic shock).
Plasma miRNA-208a determination
Whole blood was collected in K2EDTA tubes and subjected to 
two-step centrifugation. Plasma samples were stored at –80oC. 
Total RNA containing fraction of miRNA was isolated with 
mirVana PARIS kit (Ambion) according to the protocol of the 
manufacturer. MicroRNA-208a expression was analysed us-
ing TaqMan-based real-time polymerase chain reaction (PCR) 
(Applied Biosystems). Synthesis of cDNA and qPCR reactions 
were prepared with TaqMan MicroRNA Reverse Transcrip-
tion Kit (Applied Biosystems) and TaqMan MicroRNA assay 
(Applied Biosystems) according to the manufacturer’s proto-
cols. qRT-PCR reactions were carried out on a 7500 Real-Time 
PCR System (Applied Biosystems). The relative expression level 
of miRNA-208a was calculated using the ddCt method. The 
HY3 molecule was used as an endogenous control. 
Biochemical analyses
We measured hs-cTnI and CK-MBmass by using the Dimen-
sion Xpand Plus Integrated Chemistry System. The analytical 
sensitivity of cTnI assays were determined to be less than 
0.015 ng/mL. Functional sensitivity of cTnI is defined as the 
lowest concentration of cTnI with a total precision (%CV) 
of 10%, based on a two replicate per run, one run per day, 
20-day reproducibility study. Five serum samples were tested, 
and the troponin I concentration with a 10% total CV was read 
from the curve. The functional sensitivity was determined to 
be approximately 0.04 ng/mL.
Statistical analyses 
Statistical analysis was performed using Statistica 8.0. In the 
process of hypothesis testing the level of significance was set 
at p < 0.05, where the choice is up to the researcher sided 
critical region. Results with non-normally distribution are pre-
sented as the median value and interquartile range. Between 
group comparisons of distributions were used the Wilcoxon 
rank test. Correlations among continuous variables were used 
the Spearman’s rank correlation coefficient. Categorical vari-
ables are expressed as numbers (percentages) and analysed 
using Fisher’s exact test. 
RESULTS 
Clinical characteristics of the study groups are listed in Ta-
ble 1. The STEMI population were mostly male (78.9%), and 
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a history of previous MI or chronic advanced kidney disease, 
and the median concentration of creatinine was 0.89 mg/dL 
(Q1–Q3: 0.775–1.005). Furthermore, 87.5% of patients un-
derwent coronary angiography, with no findings of significant 
(> 50% stenosis) changes in the coronary arteries.
Concentrations of miRNA-208a were measured in the 
plasma of 12 healthy controls, in eight patients with stable 
CAD, and in 19 patients with STEMI. Detectable concentra-
tions of miRNA-208a were seen in only one of the controls 
and in two patients from the CAD group. However, miRNA 
expression in these groups was weak and very close to the 
limit of detection of the assay. The mean level of expres-
sion of miRNA-208a in these subjects was used to calculate 
the increase of miRNA-208a (fold change) in patients with 
STEMI (Fig. 1). A significant increase of the level of plasma 
miRNA-208a on admission (time 0) in patients with STEMI 
was observed. Plasma concentration of miRNA-208a in-
creased within the first 3 h after presentation and reminded 
increased until 12 h. In the time points 6 h and 12 h the level 
of miRNA-208a was still significantly higher than those at 
0 time. After 24 h and 48 h the concentration of miRNA-208a 
return to the baseline level.
We next determined the serum concentrations of tra-
ditional cardiac markers: cTnI and CK-MBmass (Fig. 2). It is 
noteworthy that the concentrations of both cTnI and CK-MB-
mass were below the cut off for MI at the time of admission. 
The maximum concentrations of both cardiac biomarkers 
6 h after admission were stated. The levels of cTnI as well as 
CK-MBmass were increased during observation up to 48 h. 
the median age was 58.0 years (Q1–Q3: 54.5–65.5). Three 
(15.7%) patients had a history of previous MI. No patients had 
any history of advanced chronic kidney disease, and median 
concentration of creatinine was 0.9 mg/dL (Q1–Q3: 0.81– 
–1.01). The median duration of acute symptoms to the collec-
tion of the first blood sample for isolation of miRNA-208 was 
130 min (Q1–Q3: 100–140). In 63.1% of STEMI patients the 
infarct-related artery was completely occluded, in the rest of 
the patients (36.9%) it was critically narrowed (at least 90% of 
the diameter). The left main artery was not the culprit vessel 
in any of the cases. In all STEMI patients, markers of myocar-
dial necrosis (cTnI, CK-MBmass) were significantly elevated, 
exceeding the 99th percentile standard for the laboratory. 
The initial diagnosis of a STEMI was confirmed in all patients 
enrolled to the STEMI group. One patient had a ventricular 
fibrillation during PCI. None of the patients had acute heart 
failure manifesting as a pulmonary oedema or cardiogenic 
shock. Echocardiography was performed in the subsequent 
days of hospitalisation, and the median left ventricular ejec-
tion fraction was 50% (Q1–Q3: 46–54.5%). 
In the stable CAD group 41.7% were male, and the 
median age was 66 years (Q1–Q3: 61.75–74.25). None of 
the patients had a history of previous MI or chronic advanced 
kidney disease; median concentration of creatinine was 
0.96 mg/dL (Q1–Q3: 0.885–1.123). All patients had a coro-
nary angiography, and in 66% cases there was at least 50% 
stenosis in at least one coronary artery.
In the control group 37.5% were men, the median age 
was 60.5 years (Q1–Q3: 58–67.5). None of the patients had 
Table 1. Clinical characteristics of the study groups. Results are expressed as medians (Q1–Q3)













Age [years] (Q1–Q3) 60 (58–67) 66 (62–74) 58 (55–65) 0.068 0.141 0.022
Male 3 (37.5%) 5 (41.7%) 15 (78.9%) 0.612 0.037 0.035
Previous MI 0 (0%) 0 (0%) 3 (15.7%) 0 0.233 0.148
Hypertension 7 (87.5%) 10 (83.3%) 7 (36.8%) 0.656 0.016 0.011
Diabetes 1 (12.5%) 1 (8.3%) 3 (15.8%) 0.653 0.663 0.546
Glucose [mg/dL] (Q1–Q3) 100 (89–110) 93 (79–131) 105 (97–115) 0.329 0.241 0.134
Hyperlipidaemia 6 (75%) 1 (8.3%) 13 (68.4%) 0.002 0.558 0.001
TC [mg/dL] (Q1–Q3) 172 (141–214) 153 (139–198) 207 (188–219) 0.231 0.069 0.021
TG [mg/dL] (Q1–Q3) 90 (53–150) 140 (107–169) 114 01 (107–173) 0.061 0.046 0.262
HDL [mg/dL] (Q1–Q3) 63 (44–87) 43 (37–55) 42 (39–48) 0.039 0.005 0.210
LDL [mg/dL] (Q1–Q3) 85 (68–114) 86 (71–118) 135 (116–150) 0.481 0.003 0.004
Creatinine [mg/dL] (Q1–Q3) 0.93 (0.74–1.22) 1.04 (0.85–1.21) 0.92 (0.83–0.98) 0.221 0.407 0.073
eGFR > 60 [mL/min] 2 (25%) 5 (41.7%) 2 (10.5%) 0.392 0.334 0.043
eGFR > 30 [mL/min] 6 (75%) 7 (58.3%) 17 (89.5%) 0.392 0.334 0.043
MI — myocardial infarction; TC — total cholesterol; TG — triglycerides; HDL — high density lipoprotein; LDL — low density lipoprotein; eGFR — 
estimated glomerular filtration rate; CAD — coronary artery disease; STEMI — ST segment elevation myocardial infarction 
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To eliminate the possibility that the observed increase in plasma 
miRNA-208a was caused by nonspecific insult we also deter-
mined whether plasma miRNA-208a expression measured at 
peak (3 h) correlated with the level of both cardiac biomark-
ers, also measured at the peak their concentrations (6 h). As 
presented in Figure 3, we observed significant correlations 
between changes of miRNA-208a and cTnI and CK-MBmass 
released from the infarct area. 
DISCUSSION
The first biomarkers of tissue injury were enzymes that are 
released into circulation after injury. The subsequent devel-
opment of immunoassays that quantified proteins expanded 
the repertoire of specific cardiac proteins of potential clinical 
utility in the diagnosis of AMI and heart failure. Many of these 
markers have shortcomings such as reduced sensitivity, insuf-
ficient specificity or extended time to diagnosis [3, 4]. Cardiac 
troponins are currently the best validated biomarkers for the 
diagnosis of AMI. However, measurable amounts of troponin 
proteins are usually not released from damaged myocardium 
within 4–8 h of onset of symptoms [2, 3].
Recent advances in molecular biology and technology 
have initiated considerable interest in nucleotide-based bio-
markers [9]. Accumulating evidence suggest the usefulness 





Figure 1. Time course of miRNA-208a plasma levels in patients 
with ST-segment elevation myocardial infarction
Figure 2. Time course of cardiac troponin I (cTnI) and creatinine 
kinase (CK)-MBmass plasma levels in patients with ST-segment 
elevation myocardial infarction
Figure 3. Correlation between miRNA-208a and cardiac  
troponin I (cTnI) (A) and miRNA-208a and creatinine  
kinase (CK)-MBmass (B)
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the detection of tissue injury [10–14]. Various studies have 
demonstrated that miRNAs are released into the peripheral 
blood during AMI [15–18]. Increased circulating levels of 
miRNA-1, miRNA-133a, miRNA-133b, and miRNA-499, 
which are highly expressed in the skeletal muscle as well as 
in the heart, were observed in several studies investigating 
AMI patients and animal models [19, 20]. 
In terms of specificity, cardiac-restricted miRNA-208 rep-
resents a very attractive candidate. MicroRNA-208 is encoded 
by an intron of the alpha-myosin heavy chain gene. The 
miRNA-208 family includes two subfamilies: miRNA-208a 
and miRNA-208b. miRNA-208 is involved in cardiomyocyte 
hypertrophy, fibrosis, and regulation of other cardiac muscle 
gene expression and function [21]. Two studies found that 
miRNA-208 was very low or absent in control subjects and that 
its plasma levels were sharply increased upon AMI [18, 22]. 
However, other human studies measured detectable levels of 
miRNA-208 only in a sub-set of AMI patients, questioning the 
sensitivity of miRNA-208 as an AMI biomarker [20, 23]. Inter-
esting results were reported by Fichtlscherer et al. [24], who 
found that in patients with stable CAD, plasma miRNA-126, 
miRNA-17, miRNA-92a, and miRNA-155 were decreased, 
while miRNA-133a and miRNA-208a were increased. 
Our data show that the plasma concentration of 
miRNA-208a, which is produced exclusively in the heart, 
increases in STEMI and/or reperfusion-induced myocardial 
injury. Circulating miRNA-208a was hardly detectable, very 
close to the detection limit of the assay in healthy humans 
and in patients with stable CAD. A rise in miRNA-208a in 
plasma was evident (10-fold increase) at the time of admis-
sion (less than 3 h after onset of chest pain) in patients with 
STEMI when cTnI was not yet affected. This indicates that 
miRNA-208a may leak into the bloodstream at an earlier 
stage of myocardial injury. In addition, miRNA-208a achieved 
its peak before both cTnI and CK-MBmass (3 h vs. 6 h, re-
spectively). The plasma expression of miRNA-208a shows 
a good correlation with the classic markers of myocardial 
damage at the time of their maximal concentrations. More 
recently, unexpected results were published by Nabialek et 
al. [25]. It was demonstrated in this study that circulating 
serum miRNA-208a levels are unchanged in AMI patients at 
six, 12, and 24 h after PCI. These differences may be due to 
the measuring time. It is possible that these time-points rep-
resent the times in which the release of miRNA-208a into the 
circulation is decreasing. In a very interesting study, Zile, et 
al. [26] demonstrated late release of miRNA-208 in patients 
after MI. The miRNA-208 increased five days post AMI and 
remained elevated for up to 90 days. These time-dependent 
changes were accompanied by a progressive increase of left 
ventricular and diastolic volume. From our and other results it 
may be suggested that the release of miRNA-208 after onset 
of AMI is biphasic. Early release is probably due to myocardial 
ischaemia and, in contrast, late release to metabolic changes 
leading to left ventricular structural remodelling. 
However, the release mechanism of miRNAs is unclear, 
but they may be freed to the bloodstream as a consequence 
of passive release of the cell contents as apoptotic bodies, ex-
osomes, and microparticles [27, 28]. Microparticles containing 
miRNAs may be formed during myocardial ischaemia as well 
as during necrosis. The findings of our study do not enable us 
to establish whether circulating miRNA-208a is an indicator 
of cardiac necrosis and/or myocardial ischaemia. Early release 
(before cTnI) and decrease after successful reperfusion seem 
to suggest that miRNA-208a is marker of myocardial ischaemia 
rather than necrosis. 
Limitations of the study
It should be noted that the consideration of circulating 
miRNA-208a as a biomarker for AMI is at present based on 
the results from a relatively small sample. Larger clinical stud-
ies are definitely required to establish the clinical usefulness 
of miRNAs in the early diagnostics of MI. Nonetheless, the 
present study lays the groundwork for future efforts to establish 
precise mechanisms leading to expression of miRNA-208a in 
the circulation after AMI and also to identify of miRNA-208a 
as a novel class of cardiac biomarker and its diagnostic and 
prognostic significance.
CONCLUSIONS
There is an increased level of miRNA-208a plasma concentra-
tion in STEMI patients, not detected in stable CAD undergo-
ing PCI and individuals without coronary disease. In STEMI 
patients the miRNA-208a increases within first 3 h after onset 
of chest pain, before any rise of cTnI and CK-MBmass is 
detected. MicroRNA-208a exhibited a very short life in the 
circulation during AMI and may be promising new marker 
for early AMI diagnosis. 
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S t r e s z c z e n i e
Wstęp: Biochemiczne potwierdzenie zawału serca bazuje na oznaczaniu stężenia troponin sercowych: cTnI lub cTnT. Wiele 
badań wskazuje, że nowym obiecującym biomarkerem uszkodzeń narządowych mogą być cząsteczki mikroRNA (miRNA).
Cel: Celem badania było określenie kinetyki ekspresji krążącego miRNA-208a oraz weryfikacja hipotezy, że krążące cząsteczki 
sercowo swoistego miRNA-208a mogą być użytecznym markerem diagnostycznym zawału serca z przetrwałym uniesieniem 
odcinka ST (STEMI).
Metody: Przebadano 19 pacjentów z STEMI (4 kobiety i 15 mężczyzn w wieku 44–85 lat), 12 osób ze stabilną chorobą 
wieńcową (CAD) oraz 8 osób z negatywną obserwacją CAD jako grupę kontrolną. Krew pobierano w momencie zgłoszenia 
(czas 0) oraz po 3, 6, 12, 24 i 48 godzinach; w grupie CAD i kontrolnej krew do badań pobierano jednorazowo. Osoczowy 
miRNA-208a oznaczano w rekcji RT-PCR i obliczano jego względny przyrost. W próbkach surowicy krwi oznaczano stężenie 
cTnI i CK-MBmass. 
Wyniki: Oznaczalne, podwyższone stężenie miRNA-208a stwierdzono u pacjentów z STEMI w momencie przyjęcia, podczas 
gdy w grupie CAD i kontrolnej było bardzo niskie, w wielu przypadkach nieoznaczalne. Najwyższe stężenia miRNA-208a 
zaobserwowano w trzeciej godzinie po reperfuzji (p < 0,001). Tradycyjne biomarkery cTnI i CK-MBmass wzrastały później, 
osiągając maksimum w 6. godzinie po reperfuzji. Stężenie krążącego miRNA-208a silnie korelowało ze stężeniami uwolnio-
nych z obszaru zawału cTnI i CK-MBmass.
Wnioski: Uzyskane wyniki wskazują, że miRNA-208a jest obiecującym markerem uwalnianym do krążenia we wczesnej fazie 
zawału, który może być przydatny w jego diagnostyce.
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